Herzliya, Israel-based TriVentures, a venture capital fund focused on investing in medical device and digital health technologies from seed stage to industry leaders, has reportedly raised $75 million for its TriVentures III Fund, according to Israeli media. The offering had initially been disclosed in a Form D filed with the SEC on September 30, 2014.

TriVentures has over $100 million under management dedicated to ventures primarily in Israel and the United States. The firm’s co-founders are Michal Geva, Dr. Peter Fitzgerald and Dr. Martin Leon.

The firm’s strategic partners include medical technology companies Medtronic (NYSE:MDT), Abbott Laboratories (NYSE:ABT), Volcano (NASDAQ:VOLC), Thoratec (NASDAQ:THOR), Cardinal Health (NYSE:CAH), Intermountain Healthcare, Encarta Health Ventures, Edmond de Rothschild and Boston Scientific, and a wide variety of successful medical device investors and entrepreneurs from the U.S., Israel, Europe, China, India, South Korea and Japan.

TriVentures is uniquely structured to provide guidance in research and development, intellectual property, clinical studies, regulatory pathways, market integration and business development. The firm has experience with medical startups, from transitioning dozens of companies and from having taken several companies public.

Michal Geva is the Managing Partner of Triventures. She has 20 years of professional experience in Israeli and American medical device companies. Since the founding of Triventures, she has co-led the funding of two venture funds with strategic and financial investors. She has also led nine investments in the fields of cardiovascular, orthopedic, surgery, women’s health and digital health. Her investments have been from pre-seed stage all the way to late stage deals. Geva currently sits on the boards of a number of companies, including Apica and ApK (transitioned to Thoratec), OrthoSpace (partnered with Smith & Nephew), MST (a robotic laparoscopic surgery platform), MediSafe (a patient engagement platform) and BioGaming (rehab gamification). Prior to Triventures, she held executive roles in regulatory and clinical affairs, and in business development at a number of startups including ByPass (collaborated with J&J), AST (acquired by Boston Scientific), and GI View (in the field of gastroenterology).

Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 150 clinical trials, published over 450 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine in the past decade. In addition, he heads the Stanford/Asia MedTech innovation program.

Dr. Fitzgerald has been principal/founder of eighteen medical device companies in the San Francisco Bay Area. He has transitioned twelve of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Dr. Fitzgerald was part of the founding team of LVP Capital, a venture firm that has raised three funds focused on medical device and biotechnology start-ups in San Francisco. In 2009, he co-founded Triventures and dedicates a significant portion of his time working closely with the companies, coming to Israel once a month.

Dr. Martin Leon is Professor of Medicine at Columbia University Medical Center (CUMC). Dr. Leon is also Director of the Center for Interventional Vascular Therapy (CIVT), Director of the Cardiac Catheterization Laboratories, and on the Executive Board of the Columbia New York Presbyterian Heart Valve Center. He continues as a practicing Interventional cardiologist at New York-Presbyterian Hospital in New York City. Dr. Leon is the Founder and Chairman Emeritus of the Cardiovascular Research Foundation. Dr. Leon has served as principal investigator for over 50 clinical trials that have helped shape the field of interventional cardiovascular medicine, including the following studies: STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, and most recently, the PARTNER trial, studying the value of transcatheter valve therapy for patients with aortic stenosis.

Dr. Leon has co-authored over 1550 publications, has performed over 10,000 interventional procedures, and has had a major impact as a thought-leader and innovator in the expanding sub-specialty of interventional cardiovascular device and drug therapies. He is the Director and Founder of Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier interventional cardiovascular meeting, which recently celebrated its 26th anniversary. Dr. Leon has also served as Director or Co-Director of more than 100 international educational programs in areas of interventional cardiology. Dr. Leon has received 10 international career achievement awards and was awarded an honorary degree from the University of Athens. Dr. Leon was previously the Director of Cardiovascular Research and Education at the Lenox Hill Heart and Vascular Institute in New York. Prior to that, he was Director of Clinical Research at the Washington Cardiology Center at the Washington Hospital Center and Clinical Professor of Medicine at Georgetown University Medical Center in Washington, DC. Earlier in his career, he served as a Clinical Associate, Senior Investigator, and Director of the Catheterization Laboratories in the Cardiology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, MD. He was a founder of the Washington Cardiology Center and the Cardiology Research Foundation in Washington, DC. Dr. Leon completed a fellowship in Cardiology at the Yale-New Haven Hospital. He completed medical school at the Yale School of Medicine, and his internship and residency in internal medicine at the Yale-New Haven.



Thank you for contacting ExitHub. We'll respond as soon as possible.


© 2018 ExitHub Inc. All Rights Reserved.

Log in with your credentials


Forgot your details?

Create Account